Corbus Pharmaceuticals Holding (CRBP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $69.86M
Last updated: Nov 17, 2026 at 11:04 AM ET
Corbus Pharmaceuticals Holding (CRBP) Stock Forecast
Analysts expect Corbus Pharmaceuticals Holding (CRBP) to earn -$6.08 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$6.08
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$5.32
- EPS consensus, revenue $442860
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$6.08 | -$6.89 to -$5.17 | 9 | N/A | N/A | 7 |
| Dec 31, 2027 | -$5.32 | -$7.06 to -$3.26 | 9 | $442860 | N/A | 7 |
Quarterly Estimates
The EPS consensus rises from -$1.42 for the quarter ending Dec 31, 2026 to -$1.21 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.42 | -$1.96 to -$0.78 | 12 |
| Mar 31, 2027 | -$1.21 | -$1.51 to -$0.96 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$5.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$6.08 | -$5.60 | -$5.43 | -$5.43 | -$5.43 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.32 | -$5.55 | -$5.51 | -$5.51 | -$5.47 | N/A |
| Quarter ending Mar 31, 2027 | -$1.21 | -$1.24 | -$1.24 | -$1.24 | -$1.24 | N/A |
Frequently Asked Questions About CRBP
What is the CRBP stock forecast?
Consensus analyst estimates put Corbus Pharmaceuticals Holding's EPS at -$6.08 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate CRBP stock?
Of 10 analysts covering Corbus Pharmaceuticals Holding, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRBP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$6.08, with estimates from -$6.89 to -$5.17 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.32, with estimates from -$7.06 to -$3.26 from 9 analysts.
What revenue do analysts expect from Corbus Pharmaceuticals Holding next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $442860.
How many analysts cover CRBP?
10 analysts rate Corbus Pharmaceuticals Holding stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRBP pages: Overview, Earnings, Forecast, Financials, Competitors